EMA Medicine safety communications
Strimvelis: adverse event
Published by European Medicines Agency: · Ref. EMEA/H/C/003854/R/0029
Summary
Adverse event
Medicine
Strimvelis
- Category
- Medicine safety communications
- Product type
- Human medicine
- Active substance(s): autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) cDNA sequence from human haematopoietic stem/progenitor (CD34+) cells
- Therapeutic area: Severe Combined Immunodeficiency
- ATC code: L03
Measures and alternatives
- Regulatory outcome: Maintenance
Source: EMA — medicine safety communications — European Medicines Agency
Source: European Medicines Agency (EMA). Reproduced with acknowledgement of the source, in line with the EMA legal notice. EU Safety Radar is an independent information service; the text above presents the official data in the original language — the notice published by the authority is authoritative.
Open the original notice (www.ema.europa.eu) ↗